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ABSTRACT Clostridium difﬁcile infection (CDI) is the leading cause of antibiotic-
associated diarrhea and has gained worldwide notoriety due to emerging hyperviru-
lent strains and the high incidence of recurrence. We previously reported protection
of mice from CDI using the antigerminant bile salt analog CamSA. Here we describe
the effects of CamSA in the hamster model of CDI. CamSA treatment of hamsters
showed no toxicity and did not affect the richness or diversity of gut microbiota;
however, minor changes in community composition were observed. Treatment of C.
difﬁcile-challenged hamsters with CamSA doubled the mean time to death, com-
pared to control hamsters. However, CamSA alone was insufﬁcient to prevent CDI in
hamsters. CamSA in conjunction with suboptimal concentrations of vancomycin led
to complete protection from CDI in 70% of animals. Protected animals remained
disease-free at least 30 days postchallenge and showed no signs of colonic tissue
damage. In a delayed-treatment model of hamster CDI, CamSA was unable to pre-
vent infection signs and death. These data support a putative model in which
CamSA reduces the number of germinating C. difﬁcile spores but does not keep all
of the spores from germinating. Vancomycin halts division of any vegetative cells
that are able to grow from spores that escape CamSA.
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Clostridium difﬁcile is an anaerobic, spore-forming pathogen that colonizes the gut ofsusceptible individuals and causes Clostridium difﬁcile infection (CDI) (1). CDI is
recognized as the leading cause of antibiotic-associated diarrhea in nosocomial envi-
ronments. CDI poses a large burden for the health care system, costing the United
States 3 billion dollars annually (2). An emergent hypervirulent C. difﬁcile strain
(BI/NAP1/027) is associated with even more severe disease (3, 4). The morbidity and
mortality rates associated with CDI have prompted the CDC to upgrade C. difﬁcile to an
urgent antimicrobial resistance threat (5).
C. difﬁcile spores are transmitted via the fecal-oral route, and CDI most often occurs
after a patient has been treated with antibiotics. In fact, most broad-spectrum antibi-
otics can render a person susceptible to C. difﬁcile (6). Antibiotic use disrupts the natural
gut microbiota that normally resists colonization by C. difﬁcile (7). In this new favorable
environment, C. difﬁcile spores germinate; the resulting vegetative cells proliferate in
the gut and release two exotoxins, toxin A and toxin B. These toxins cause injury to and
inﬂammation of the colonic lining, resulting in disease (8, 9). Because of the intrinsic
antibiotic resistance of C. difﬁcile spores and the inability of current antibiotic treat-
ments for CDI to completely clear the pathogen from the intestinal tract, nonantibiotic
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strategies should be investigated (10–14). Continued antibiotic use to treat CDI pre-
vents commensal microbiota from repopulating the gut, allowing persistent C. difﬁcile
spores to germinate and to reestablish disease. As a result, 25 to 30% of CDI patients
experience repeated bouts of relapse (15–17).
C. difﬁcile spores must germinate to establish disease. The activation of dormant C.
difﬁcile spores requires binding of the primary bile salt taurocholate and amino acids
(18, 19). We showed that a synthetic bile salt analog, CamSA, was a competitive
inhibitor of taurocholate-induced C. difﬁcile spore germination in vitro (18). Further-
more, CamSA prevents CDI in a murine model in a dose-dependent manner (20).
In the current study, we assessed the effectiveness of CamSA in the more suscep-
tible hamster CDI model. As in mice, CamSA showed no toxicity and did not cause
large-scale disruption of the hamster intestinal microbiota. CamSA alone was unable to
prevent CDI in hamsters but resulted in a delay in the onset of disease. Interestingly,
CamSA in combination with a suboptimal dose of vancomycin, administered at the
same time as C. difﬁcile spores, prevented CDI in 70% of challenged hamsters. However,
CamSA-vancomycin combinations were unable to prevent CDI recurrence when van-
comycin was administered 24 h postchallenge with C. difﬁcile spores. These results
suggest that antigermination therapies have the potential to be used in combination
with current antibiotic treatments to reduce CDI progression. This study has also
revealed limitations of CamSA alone as prophylaxis for CDI in hamsters.
RESULTS
CamSA toxicity. Hamsters treated for 30 consecutive days with the highest CamSA
dose (300 mg/kg) used in previous studies (20) showed no obvious adverse physio-
logical or behavioral effects. Similarly, gross anatomical examination of treated animals
showed no lesions or abnormalities. Microscopic examinations of colons showed no
histological anomalies, and ﬁndings were indistinguishable from those for untreated
animals (see Fig. S1 in the supplemental material).
Microbiome effects. CamSA (300 mg/kg) treatment for 30 days did not signiﬁcantly
alter the richness, evenness, or diversity of the hamster intestinal microbiome (Fig. 1).
However, nonmetric multidimensional scaling (NMDS) analysis based on Bray-Curtis
dissimilarity, along with a corresponding Adonis analysis, showed that treatment with
CamSA for 30 days led to a statistically signiﬁcant change in the community compo-
sition of hamster gut microbiomes (Fig. 2A). Bar graphs showing the relative abundance
of microbial taxa before and after CamSA treatment, along with a corresponding
FIG 1 Alpha diversity metrics comparing hamster fecal microbiomes before (day 0, n  5) (yellow circles)
and after (day 30, n  4) (blue circles) a 30-day CamSA treatment. The data for 1 hamster after CamSA
treatment failed quality control standards and was removed from the data set. Bars represent means and
95% conﬁdence intervals. No values were signiﬁcantly different before versus after CamSA treatment
(pairwise Kruskal-Wallis test, P  0.05). Observed SVs, observed sequence variants; Pielou’s E, Pielou’s
evenness; Shannon, Shannon diversity index; Faith’s PD, Faith’s phylogenetic diversity.
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SIMPER analysis, showed these shifts to be small in comparison to broad-spectrum
antibiotic treatment (Fig. 2B; also see Fig. S2 and Table S1 in the supplemental material)
(5, 6, 21). Taxa that contributed most to the variance between microbiomes before and
after CamSA treatment included a relative increase in Akkermansia (Verrucomicrobia)
and shifts in populations of unclassiﬁed Gastranaerophilales (Cyanobacteria), Prevotel-
laceae (Bacteroidetes), Lachnospiraceae (Firmicutes), and Bacteroidetes.
Delay of CDI onset by CamSA. Hamsters challenged with C. difﬁcile spores became
symptomatic rapidly and were culled within 3 days postchallenge (Fig. 3A and B).
Challenged hamsters treated with 300 mg/kg CamSA for 4 days developed CDI signs
similar to those in untreated animals and were culled, but the onset was delayed up to
7 days, leading to a statistically signiﬁcant difference (P  0.0006) in survival times
FIG 2 (A) NMDS analysis based on Bray-Curtis dissimilarity, demonstrating that gut microbiomes were signiﬁcantly
different before (CamD0) (yellow squares) versus after (CamD30) (blue squares) CamSA treatment. Numbers after the
hyphens refer to speciﬁc hamsters. Ellipses represent the standard errors of the mean (95% conﬁdence). (B) Bar plot
showing the relative abundance of gut microbiota at the genus level in each hamster before (day 0) and after (day 30)
CamSA treatment. Uncultivated and unnamed genera are listed according to the lowest named taxonomic level, as
categorized by SILVA. In cases in which the SILVA taxonomy was ﬂagged as misclassiﬁed, the Ribosomal Database Project
(RDP) taxonomy was used.
FIG 3 Effects of CamSA on hamsters infected with C. difﬁcile spores. (A) Timeline of experiments. All
hamsters were treated with a single 30-mg/kg dose of clindamycin (day1). On day 0, animals were
challenged with 100 C. difﬁcile spores. Animals were treated with either 0 or 300 mg/kg CamSA in
DMSO for 4 consecutive days beginning at day1. Animals were scored for signs of CDI twice daily.
(B) Percent survival, presented as a Kaplan-Meier survival plot, which shows a signiﬁcant difference
between CamSA-treated () and untreated (e) animals (P  0.0006).
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between CamSA-treated and untreated hamsters. Under these conditions, CamSA
alone increased the mean time to death from 1.73 to 3.77 days.
Effects of CamSA in combination with vancomycin. To determine the effects of
combining vancomycin and CamSA treatments, animals were challenged with C.
difﬁcile spores and treated with a suboptimal vancomycin dose (5 mg/kg) (22, 23) and
CamSA (300 mg/kg) (Fig. 4A). As expected, animals treated with vancomycin alone
become moribund within 9 days postchallenge. Combining vancomycin with CamSA
for 19 consecutive days resulted in asymptomatic survival of 70% of the animals (Fig.
4B). Similar results were obtained when the CamSA dosage was stopped after 10
consecutive days. In contrast, limiting CamSA treatment to 6 doses resulted in survival
of only 10% of infected animals. The increases in survival rates for hamsters treated with
vancomycin and CamSA for 6 (P  0.04), 10 (P  0.001), or 19 (P  5.18  105)
consecutive days were signiﬁcant, compared to hamsters treated with vancomycin
alone. When the CamSA dosage was reduced to 50 mg/kg for 10 days, C. difﬁcile-
challenged animals developed CDI signs, with scores indistinguishable from those of
untreated animals.
Vancomycin-CamSA-protected animals showed intact colonic mucosal lining, with
no distinct tissue damage or separation of the submucosal region, and were indistin-
guishable from control animals. In contrast, histological examination of animals show-
ing signs of CDI presented extreme intestinal tissue damage, including disruption or
loss of the colonic mucosal lining, loss of integrity of epithelial cells, and substantial
separation of the submucosa (Fig. S3).
Fecal samples from challenged animals showed only C. difﬁcile vegetative cells; no
spores were recovered. Samples were heterogeneous with regard to C. difﬁcile cells
shed and the timing needed to clear C. difﬁcile from the gastrointestinal tract. Most
vancomycin-treated control animals showed maximum shedding between 4 and 6 days
postchallenge but continued shedding until culling (Fig. 5A). CamSA-treated animals
that did not develop CDI started shedding as early as 2 days and continued until 10
days postchallenge (Fig. 5B). Animals treated with only vancomycin showed a statisti-
cally signiﬁcant (P  0.005) increase in C. difﬁcile shedding over time. In contrast,
shedding in vancomycin-CamSA-treated animals remained constant (P  0.2). These
differences in shedding behavior resulted in statistically signiﬁcant decreases in fecal C.
difﬁcile loads in vancomycin-CamSA-treated animals, compared to animals treated with
only vancomycin, at days 2 (P  0.005), 4 (P  0.042), 6 (P  0.005), and 8 (P  0.001)
postchallenge. Fecal samples were collected up to day 30 postchallenge; however, C.
difﬁcile was undetectable in fecal samples after day 12. CamSA-treated animals that
FIG 4 Protection of hamsters from CDI with combined administration of a suboptimal vancomycin dose and
CamSA. (A) Timeline of experiments. All hamsters were treated with a single 30-mg/kg dose of clindamycin (day
1). Also starting at day1, animals were treated daily with 300 mg/kg CamSA for 0, 6, 10, or 19 consecutive days.
Another group of animals was treated with 50 mg/kg CamSA for 10 consecutive days. On day 0, all animals were
challenged with 100 C. difﬁcile spores. Starting at day 0, all animals were also treated daily with 5 mg/kg
vancomycin for 3 consecutive days. (B) Percent survival, presented as a Kaplan-Meier survival plot, which shows
signiﬁcant increases in animal survival rates with 300-mg/kg CamSA treatment for 6 days (P  0.04) (), 10 days
(P  0.001) (Œ), and 19 days (P  5.18  105) (), compared to untreated animals (e). Survival of animals treated
with 50 mg/kg CamSA for 10 days () was undistinguishable from that of untreated animals.
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developed CDI shed C. difﬁcile up to culling or 10 days postchallenge (data not shown).
All data collected correspond to total C. difﬁcile found in feces. Heat treatment of feces
to obtain only C. difﬁcile spores was unsuccessful. Surviving animals from all groups did
not develop any CDI signs, even 30 days after the ﬁnal CamSA dose.
Effects of CamSA on CDI in hamsters with delayed vancomycin treatment. To
test for synergistic effects of antibiotic and antigermination treatments on CDI, vanco-
mycin treatment was started 1 day after spore challenge, as described previously
(24–26) (Fig. 6A). This delay in vancomycin dosing negated the synergistic effects of
vancomycin-CamSA combinations (Fig. 6B). There was no statistically signiﬁcant differ-
ence in survival times between hamsters treated with vancomycin and CamSA (10-day
treatment, P 0.67; 17-day treatment, P 0.25) and hamsters given vancomycin alone.
Even animals that were continuously administered CamSA daily developed CDI within
15 days after C. difﬁcile challenge, resulting in only 17 consecutive CamSA doses. The
calculated mean time to death for infected untreated animals was 7.2 days. The
calculated mean times to death for animals treated with CamSA and vancomycin for 10
and 19 consecutive CamSA doses were 6.0 days and 7.5 days, respectively.
FIG 5 Box-and-whisker plots showing total numbers of C. difﬁcile in hamster feces, including spores and vegetative cells
(mean  standard deviation). C. difﬁcile-challenged animals were treated with 5 mg/kg vancomycin only (A) or with 5
mg/kg vancomycin and 300 mg/kg CamSA (B) for 19 consecutive days. Two-way mixed ANOVA was used to assess the
signiﬁcance of differences for groups treated with vancomycin only or CamSA plus vancomycin on days 2 (P  0.005),
4 (P  0.042), 6 (P  0.005), and 8 (P  0.001). Within groups, animals treated with vancomycin only showed signiﬁcant
differences in C. difﬁcile CFU per milligram of feces over time (P  0.005), but no signiﬁcant differences were found for
the CamSA-vancomycin group (P  0.2) over time.
FIG 6 Effects of delayed treatment on CDI with combined administration of a suboptimal vancomycin dose and CamSA.
(A) Timeline of experiments. All hamsters were treated with a single 30-mg/kg dose of clindamycin (day 1). Starting at
day 1, animals were treated daily with 300 mg/kg CamSA for 0, 10, or 17 consecutive days. On day 0, all animals were
challenged with 100 C. difﬁcile spores. The beginning of vancomycin treatment was delayed for 24 h (day 1) after challenge,
and treatment was continued daily for 5 consecutive days. Animals were scored for signs of CDI twice daily. (B) Percent
survival, presented as a Kaplan-Meier survival plot. No difference in survival rate was conferred with 10 days of CamSA
treatment (P  0.67) (o) or 17 days of CamSA treatment (P  0.25) (), compared to untreated animals (e).
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Effects of CamSA analogs on CDI in hamsters. The structure of CamSA contains
a sulfonic acid moiety at the meta-position of the aromatic ring conjugated to cholic
acid (Fig. 7A). We showed previously that analogs of CamSA with the sulfonic acid
moiety in either the para- or ortho-position negated inhibition of C. difﬁcile spore
germination in vitro, but in vivo studies were not performed (18). To test the effects of
CamSA structural isomers in CDI protection, hamsters were treated with suboptimal
concentrations of vancomycin and either CapSA (para-analog) or CaoSA (ortho-analog)
for 10 consecutive days or until they were moribund (Fig. 7B). As shown above,
CamSA-treated hamsters showed a signiﬁcant increase in survival times (P  0.001),
compared to hamsters given vancomycin alone (Fig. 7C). In contrast, CapSA did not
offer protection (P  0.75), and CaoSA-treated animals showed decreased survival
times (P  0.001), compared to animals administered vancomycin alone (Fig. 7C).
DISCUSSION
C. difﬁcile spore germination is required for the establishment of CDI (11) and thus
can be used as a target for CDI prophylaxis. Using the antigerminant CamSA, we
reported the complete prevention of CDI in mice (20, 27). In this study, we extended
antigermination therapy to the more stringent hamster model of CDI.
Reportedly, mice can be quite resistant to CDI and require an aggressive regimen of
antibiotics to make them susceptible to infection (28–30). Others showed that mice can
be quite susceptible to various C. difﬁcile strains under different treatment strategies
(21, 31, 32). Even so, mice must be challenged with a nonphysiologically large number
of C. difﬁcile spores. Murine CDI signs develop slowly and follow a predictable pattern
(29, 33). Furthermore, in our experience, most mice recover within a few days (20, 27).
FIG 7 Effects of CapSA and CaoSA on CDI prevention in hamsters. (A) Structures of CamSA, CapSA, and CaoSA. (B) Timeline of
experiments. Animals were treated with clindamycin (day 1) and challenged with C. difﬁcile spores (day 0), as described above.
Vancomycin (5 mg/kg) was administered for 3 consecutive days beginning at day 0. Starting at day 1, CaoSA, CapSA, or CamSA at
300 mg/kg was administered daily to animals for 10 consecutive days or until the animals became moribund. Animals treated with
vancomycin only served as controls. (C) Percent survival, presented as a Kaplan-Meier survival plot, demonstrating that CamSA ()
offered protection (P  0.001), compared to untreated control animals (e), whereas CapSA () did not (P  0.75) and CaoSA (Œ) led
to more rapid deaths (P  0.001).
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The murine model used previously to test CamSA mimics human CDI in showing
gradual increases in CDI signs, and the murine relapse model has been reﬁned to
resemble human relapse more closely (28, 34).
Due to their high susceptibility to CDI, hamsters have been the standard CDI model.
Hamster CDI is readily fulminant after challenge with a few dozen spores (35). These
extreme symptoms are rarely seen in primary human CDI (26, 35). Indeed, hamster CDI
progresses so rapidly that it more closely resembles an intoxication than a developing
infection. However, suboptimal vancomycin treatment of infected hamsters results in
delayed sign onset, similar to human CDI relapse (23, 35). Testing the effects of CamSA
in the hamster model of CDI and CDI after delayed vancomycin treatment allowed us
to determine the limits of antigermination therapy. CamSA prevented CDI in mice in a
dose-dependent manner, even when mice were challenged with 1 million times more
C. difﬁcile spores than in the current study (20). In the more susceptible hamster model,
antigermination therapy delayed the onset of disease and prevented CDI in only 70%
of hamsters when administered for 10 doses and in the presence of a suboptimal
concentration of vancomycin.
In our hands, the antigerminant CamSA has lower efﬁcacy in protecting hamsters
from C. difﬁcile strain 630, compared to mice; this ﬁnding is not unexpected. Previous
reports have consistently shown that CDI treatment in hamsters results in worse
outcomes than in a corresponding mouse model (36–39). Furthermore, treatment
efﬁcacy is dependent on the C. difﬁcile strain used in the hamster model (40). The most
recently approved CDI treatment, ﬁdaxomicin, was able to protect 100% of hamsters
from C. difﬁcile strain ATCC 9689 (ribotype 001) (41) and 80% of animals from C. difﬁcile
strain BI1 (ribotype 027) but protected only 40% of animals from the same C. difﬁcile
strain 630 (ribotype 012) used in our experiments (25).
The role of the microbiome in preventing CDI has been used to develop probiotic
treatments (42). A recent article reported that speciﬁc normal gut bacterial species,
such as Clostridium scindens, can ameliorate CDI in mice (43). Differences in the
microbiome before and after antibiotic disruption have been reported to produce
changes in bile salt composition, which can affect C. difﬁcile spore germination (44).
Here we provide evidence, using deep sequencing of the V4 region of the 16S rRNA
gene, that CamSA treatment for 30 days induced small but statistically signiﬁcant
changes in the gut microbiota. The small increase in Akkermansia is not suggestive of
harmful dysbiosis. Akkermansia is an abundant gut inhabitant that has been linked to
gut health and resistance to obesity (45, 46). The effects of minor shifts in unclassiﬁed
Gastranaerophilales, Prevotellaceae, Lachnospiraceae, and Bacteroidetes species are dif-
ﬁcult to interpret, since no close relatives of these organisms have been isolated and
characterized. In addition, our study does not rule out other causes for changes in the
microbiome during CamSA treatment. It is possible that changes were caused by aging,
stress induced by oral gavage, or the dimethyl sulfoxide (DMSO) vehicle, rather than
CamSA. Together, these data suggest that CamSA does not induce large-scale dysbiosis
in the gut microbiome; however, more detailed work may be needed to understand
more fully the effects of CamSA on the hamster gut microbiome.
In this study, CamSA alone was unable to prevent CDI development in hamsters
even at high doses. Interestingly, CDI onset in CamSA-treated animals was delayed,
suggesting that CamSA provides some antigermination effects. However, spore germi-
nation is an irreversible process and, even if CamSA inhibits the germination of most
spores, residual spore germination into toxin-producing vegetative cells may be sufﬁ-
cient to cause colitis in hamsters. In contrast, due to their intrinsic resistance to CDI,
potentially due to colonization resistance of natural microbiota, mice can tolerate the
germination of a few spores without developing CDI signs (30, 42). It is important to
note that in this study we were unable to test the direct effect of CamSA on spore
germination in the hamsters, as was conducted in the murine study (20, 27). We were
unable to recover C. difﬁcile spores from fecal samples, likely due to the small number
of C. difﬁcile spores used for challenge (100 spores). Hypotheses and extrapolations
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based on the antigermination effects of CamSA in the hamster model are based on
previous studies in vitro and in the murine model (18, 20, 27).
Vancomycin has been shown to temporarily protect hamsters from CDI, and the
onset and severity of disease can vary, depending on whether vancomycin is admin-
istered at the time of infection or 1 day following infection (23, 24, 47). Furthermore,
lower concentrations of vancomycin show suboptimal protection and result in delayed
CDI onset (23, 47). Treatment of C. difﬁcile-challenged hamsters with low-dose vanco-
mycin failed to prevent CDI but delayed the onset of disease. Combining 300 mg/kg
CamSA with suboptimal concentrations of vancomycin administered prophylactically
protected most hamsters from both immediate and delayed CDI onset. In fact, surviving
animals did not develop CDI even 30 days after CamSA treatment ended. In mice, 50
mg/kg CamSA was sufﬁcient to protect animals from CDI (20), but this same dose did
not prevent CDI in hamsters when administered alone (data not shown) or in combi-
nation with suboptimal doses of vancomycin. We postulate that the two treatments
work synergistically. CamSA prevents most C. difﬁcile spores from germinating, as seen
previously in mice (27). Indeed, animals cotreated with CamSA and vancomycin showed
signiﬁcant reductions in C. difﬁcile loads, compared to animals treated with vancomycin
alone (compare Fig. 5A and B). C. difﬁcile shedding throughout CamSA-vancomycin
treatment remained constant over the course of 10 days, while animals treated with
only vancomycin showed an increase in shedding of C. difﬁcile between day 2 and day
6. CamSA treatment may also allow the excretion of ungerminated spores, thus
signiﬁcantly reducing the infective load of C. difﬁcile (27). The number of spores
required to initiate disease in hamsters, i.e., 100 spores, is 6 orders of magnitude lower
than the number needed to infect mice (27, 29, 48). The greater spore load in mice
allowed easy recovery of C. difﬁcile from feces, for calculation of spore versus vegetative
cell excretion (20, 27). Unfortunately, in this study we were unable to separate spores
from vegetative cells; therefore, C. difﬁcile found in hamster feces is reported as total C.
difﬁcile.
Vancomycin can prevent germinated spores from proliferating in the hamster gut.
Indeed, there is a strong correlation between the transit time of C. difﬁcile spores in the
hamster gut and the length of CamSA treatment necessary to protect animals. Animals
stopped shedding C. difﬁcile cells by day 10 postchallenge, and antigermination
therapy must be continued for at least the same amount of time to be effective. This
correlation is strengthened by the ﬁnding that delaying vancomycin treatment for 24
h (day 1) eliminated CDI protection (Fig. 6B), with all animals succumbing by day 15,
compared to 70% survival in animals treated with vancomycin on day 0 (Fig. 4B). This
delay in vancomycin treatment potentially allows a few spores to germinate into
vegetative cells, which could start producing toxins (49). At that point, hamsters’
intestines are irrevocably compromised.
CamSA is a meta-aminosulfonate cholate derivative that has been shown to inhibit
C. difﬁcile spore germination effectively in vitro and in mice (18, 20) and to reduce the
incidence of CDI in hamsters in combination with vancomycin. In contrast, the ortho-
isomer (CaoSA) and the para-isomer (CapSA) of CamSA did not inhibit C. difﬁcile spore
germination in vitro (18). However, due to the highly dynamic nature of in vivo testing
(50), these isomers were assessed for activity in hamster CDI. As expected, both CaoSA
and CapSA were ineffective in the prevention of CDI in hamsters, even when combined
with vancomycin. These data support earlier hypotheses that putative C. difﬁcile spore
germination receptors are very selective in binding germinants and inhibitors such as
CamSA (19, 51, 52).
In conclusion, CamSA is a nontoxic, highly valuable tool for the investigation of C.
difﬁcile spore germination in rodent models of CDI. Importantly, CamSA does not cause
major changes to the gut microbiota. CamSA reduces the incidence of CDI in hamsters
when administered in conjunction with low doses of vancomycin. In this study, CamSA
was unable to prevent CDI recurrence in hamsters. Antigermination treatments con-
tinue to prove to be a novel method worth further exploration for the prevention of CDI
and the elucidation of this disease in vivo.
Howerton et al. Antimicrobial Agents and Chemotherapy
October 2018 Volume 62 Issue 10 e02251-17 aac.asm.org 8
 o
n
 O
ctober 16, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Materials. Bile salts were purchased from Sigma-Aldrich (St. Louis, MO) or were synthesized in the
Abel-Santos laboratory (18). Clostridium difﬁcile selective agar (CDSA) and brain heart infusion (BHI)
medium were purchased from BD Biosciences (Franklin Lakes, NJ). ChromID C. difﬁcile agar was pur-
chased from bioMérieux (Marcy l’Etoile, France), and the PRO disc kit was purchased from Remel (Lenexa,
KS). C. difﬁcile strain 630 (ATCC BAA-1382) was purchased from ATCC (Manassas, VA). Reagents for DNA
isolation were obtained from Qiagen (product no. 51504; Qiagen, Germantown, MD). Reagents for PCR
were obtained from Quantabio (product no. 2200410; Quantabio, Beverly, MA).
Animals. The institutional animal care and use committee at the University of Nevada, Las Vegas,
approved the animal protocol (protocol R0411-266) used in this study. All experiments were performed
according to the National Institutes of Health guidelines in the Guide for Care and Use of Laboratory
Animals. Weaned female golden Syrian hamsters (3 to 4 weeks of age) were purchased from Harlan
Laboratories (Indianapolis, IN) and Charles River (Wilmington, MA). Animals were housed individually and
fed ad libitum. Water, food, and bedding were autoclaved prior to use. Animals were allowed to acclimate
in the animal facility for 1 week. The following protocols involved animals 5 to 8 weeks of age. Animals
were divided into experimental groups of 5, and each experiment was repeated at least twice, with the
exception of the CamSA analog experiment (described below).
CamSA toxicity. Three groups of 5 hamsters each were analyzed for CamSA-mediated toxicity. The
ﬁrst group was treated with 135 l of DMSO, by oral gavage, once daily for 30 days, the second group
was treated with 300 mg/kg CamSA dissolved in DMSO, by oral gavage, once daily for 30 days, and the
third group received water ad libitum. Animals were weighed daily and observed for external signs of
toxicity. Fecal samples were collected and analyzed as discussed below. On day 30, hamsters were
sacriﬁced and their colons were removed for histological studies.
Histology. Colon tissue was sectioned and prepared for histological analysis as described previously
(24, 53). Brieﬂy, tissues were snap-frozen in Cryo-OCT (Thermo Scientiﬁc, Waltham, MA) and stored at
80°C. Ultrathin sections were prepared using a Vibratome UltraPro 5000 cryostat set at 50 nm. Tissue
samples were ﬁxed for 15 min in cold acetone and stored at 80°C. Samples were stained using the
Rapid Chrome hematoxylin and eosin (H & E) kit (Thermo Scientiﬁc, Waltham, MA) and visualized by light
microscopy. Colon samples were blindly evaluated for epithelial damage, integrity of the mucosal lining,
and separation of the submucosa.
Effects of CamSA on the hamster microbiome. Fecal samples for microbiome analysis were
collected aseptically, within 3 h after deposition, on day 0 and day 30 from a cohort of 5 hamsters treated
with either DMSO or 300 mg/kg CamSA. Fecal samples from DMSO-treated hamsters and CamSA-treated
hamsters were resuspended in Qiagen ASL buffer, ﬂash frozen, and archived at 80°C. DNA was
harvested from freshly thawed samples using the QIAamp DNA stool minikit and was quantiﬁed using
a NanoDrop 2000 spectrophotometer. Ampliﬁcation and sequencing of the V4 region of 16S rRNA genes
of bacteria and archaea were performed as described by Kozich et al. (54), with the following modiﬁ-
cations: (i) to be more inclusive of several archaeal lineages, forward primer 515F was modiﬁed to contain
a C or T at the 4th position from the 5= end (5=-GTGYCAGCMGCCGCGGTAA) (55), and a corresponding
modiﬁcation was made to the read 1 sequencing primer; (ii) 5 Prime HotMasterMix DNA polymerase was
used; (iii) 33 cycles were used for PCR; and (iv) sequencing on the Illumina MiSeq platform was performed
at Micro-Seq Enterprises (Las Vegas, NV). Paired-end Illumina MiSeq reads were quality ﬁltered, aligned,
and analyzed using Qiime2 (56). A single sample (CamSA treatment, day 30, hamster 5) yielded fewer
than 1,000 quality sequences and was removed from analysis. The remaining reads were truncated at the
ﬁrst position with a PHRED score of30, quality ﬁltered, and clustered into sequence variants (SVs) using
the q2-dada2 plugin (57) in Qiime2 version 2017.6 (56). Each SV was classiﬁed under the SILVA NR 99
reference database (version 128), using the classify-sklearn function of the q2-feature-classiﬁer plugin
(56). SVs identiﬁed as mitochondrial, chloroplastic, or from an unknown domain were removed. SVs were
aligned using mafft (58) through the q2-alignment plugin, with default settings. Samples were rariﬁed to
contain 13,318 features. Alpha diversity metrics (richness, Shannon diversity, Faith’s phylogenetic diver-
sity, and Pielou’s evenness) were calculated using the q2-diversity plugin (56). Kruskal-Wallis tests were
performed in R version 3.4.1 (56). Proportions of taxa at each taxonomic rank were calculated using the
R package phyloseq version 1.20.0 (59) and were visualized using ggplot2 version 2.2.1 (60). Bray-Curtis
dissimilarity, Adonis, and SIMPER analyses were performed using phyloseq and vegan version 2.4.4 (61),
and results were visualized with NMDS using vegan. Adonis partitions the variance similar to analysis of
variance (ANOVA) and tests whether the variation within a category is smaller or larger than the variation
between categories; it calculates a pseudo-F value, a P value, and a correlation coefﬁcient (R2). Data
categories with Adonis P values of 0.05 were considered signiﬁcantly different.
Preparation of C. difﬁcile spores. Spores were puriﬁed following the method described by How-
erton et al. (20). Brieﬂy, C. difﬁcile 630 was plated on BHI agar supplemented with 1% yeast extract, 0.1%
L-cysteine HCl, and 0.05% sodium taurocholate, to yield single-cell clones. Individual C. difﬁcile colonies
were grown in BHI broth and replated to conﬂuence. Plates were incubated anaerobically for 7 days at
37°C. Bacterial lawns were harvested by washing with ice-cold nanopure water and gentle scraping. The
cell mass was pelleted and washed three times. Pellets were then centrifuged through a Histodenz
gradient. Puriﬁed spores were washed and analyzed using the Shaeffer-Fulton staining method (62), to
ensure 95% pure spores.
Before infection, C. difﬁcile spores were heat activated at 68°C for 30 min and washed. Puriﬁed spores
were resuspended in water to an optical density at 580 nm (OD580) of 1.0. Spore aliquots were serially
diluted onto supplemented BHI agar to enumerate CFU.
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Effects of CamSA on CDI. To determine the effects of CamSA on hamster CDI, 30 animals were
orogastrically dosed with 30 mg/kg clindamycin 1 day prior to infection (day1). On day 0, animals were
challenged with 100 C. difﬁcile spores (25, 48). A test group (n 15) was treated daily with CamSA at 300
mg/kg, by oral gavage, for 4 consecutive days starting at day1. An infected control group (n 15) was
treated with DMSO, also by oral gavage. Fecal samples were collected using sterilized spatulas, at
preselected time points (see below). Animals were observed twice daily and scored for CDI sign
progression based on the following rubric: mild lethargy (score of 1), severe lethargy (score of 2),
wet/sticky feces (score of 1), runny diarrhea (score of 2), wet tail and pink anogenital area (score of 1),
wet anogenital area (score of 2), hunched posture (score of 2). Animals scoring 5 were considered
moribund and were euthanized. Animals scoring 1 were indistinguishable from uninfected controls.
Enumeration of C. difﬁcile from hamster feces. Fecal samples were weighed and homogenized in
sterile water to a concentration of 0.05 mg/ml. An aliquot of the fecal suspension was heated to 68°C for
15 min. Heated and unheated fecal samples were serially diluted and plated on CDSA and ChromID C.
difﬁcile selective agar (63, 64). Plates were incubated anaerobically for 48 h, and CFU were counted. CFU
obtained from unheated samples represent the sum of C. difﬁcile vegetative cells and spores. CFU
obtained from heated samples represent the number of C. difﬁcile spores only. The PRO disc kit was used
to conﬁrm C. difﬁcile identity (63, 65).
Effects of coadministration of CamSA and vancomycin. Animals were treated with 30 mg/kg
clindamycin, by oral gavage, 1 day prior to challenge (day 1). On day 0, animals were challenged with
100 C. difﬁcile spores, by oral gavage. Vancomycin (5 mg/kg) was administered once daily for 3
consecutive days starting at day 0, also by oral gavage (22–24). Starting at day 1, animals were treated
once daily with 0 mg/kg (n  10) or 300 mg/kg CamSA for 6 (n  10), 10 (n  10), or 19 (n  10)
consecutive days. Another group of animals (n  4) was treated with a lower dose of CamSA (50 mg/kg)
for 10 consecutive days or until the animals were moribund. CamSA or DMSO (control) was administered
by oral gavage. CDI signs were scored up to 30 days post-CamSA treatment. Fecal samples were analyzed
as described above. Selected animals from control groups and the 19-day CamSA treatment group were
necropsied after euthanasia, their gastrointestinal tracts were removed and observed for visual signs of
disease, and the colons were evaluated by histological staining.
Effects of coadministration of CamSA analogs CaoSA and CapSA on hamster CDI. CamSA is a
meta-aminosulfonate cholate analog. To determine whether the para- or ortho-isomers of CamSA
prevent CDI in hamsters, C. difﬁcile-challenged hamsters were treated with 5 mg/kg vancomycin, as
described above. Starting at day 1, 300 mg/kg of the meta-analog CamSA (n  10), the ortho-analog
CaoSA (n  5), or the para-analog CapSA (n  5) (18) was administered once daily by oral gavage for 10
consecutive days or until animals became moribund. CDI signs were scored as described above.
Effects of coadministration of CamSA and vancomycin in a CDI delayed-treatment model.
Following previous models for CDI relapse (23, 24, 26, 66), clindamycin-treated hamsters were challenged
with C. difﬁcile spores, as described above. The beginning of vancomycin treatment (5 mg/kg) was
delayed for 24 h after the challenge (day 1), and vancomycin was administered once daily for 5 days.
Starting at day 1, animals were also administered 300 mg/kg CamSA once daily for 10 days (n  10)
or 17 days (n  20) or until the animals became moribund. The remaining challenged animals (n  10)
were treated with DMSO. All treatments were administered by oral gavage. CDI signs were scored as
described above.
Statistical analysis. Microbiome data were analyzed statistically using pairwise Kruskal-Wallis tests
(alpha diversity) or Adonis (beta diversity), as described in more detail above. Hamster survival was
assessed by Kaplan-Meier analysis. Statistical comparisons of survival curves were calculated using a
log-rank test in R. The scores for the severity of signs were analyzed as box-and-whisker plots. Data were
expressed as the mean  standard deviation in box-and-whisker plots. Standard deviations represent at
least 3 independent measures. Student’s unpaired t test was used to determine the signiﬁcance of
differences of means. The data on CFU per milligram of feces were analyzed as box-and-whisker plots.
A two-way mixed ANOVA was performed to assess the signiﬁcance of the differences of between-group
means (CFU per milligram of feces for untreated hamsters versus CamSA-treated hamsters per day) and
within-group means (changes in CFU per milligram of feces over time within experimental groups). The
5 hamsters that died by day 8 in the control group were excluded from this analysis because of the
criteria for the ANOVA calculation.
Accession number(s). Files containing the original unﬁltered sequences are available from the NCBI
Sequence Read Archive under project no. PRJNA376248. The following Qiime2-compatible supplemental
ﬁles are available at https://github.com/hedlundb/MACamSA: metadata, unﬁltered feature table, repre-
sentative sequences, and SILVA taxonomy.
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Supplemental material for this article may be found at https://doi.org/10.1128/AAC
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